Fig 4.

Kaplan-Meier probabilities of relapse-free time (RFT) for CYP2D6 metabolizer phenotypes predicted from genotypes: A Patients not treated with tamoxifen (noTAM); B Patients treated with adjuvant tamoxifen monotherapy (mTAM); C Carriers of one or two impaired CYP2D6 alleles predictive for ‘decreased’ enzyme activity were combined; EM, IM, PM, extensive, intermediate, poor metabolizer; hetEM, heterozygous extensive. (Reprinted with permission from the American Society of Clinical Oncology: Schroth et al. [23]).